Methods for topical delivery of prostaglandins to subcutaneous fat
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/557
A61K-047/14
A61K-031/5575
A61K-047/06
A61K-047/10
A61K-009/00
출원번호
US-0702365
(2015-05-01)
등록번호
US-9849179
(2017-12-26)
발명자
/ 주소
Singer, Michael S.
Kalayoglu, Murat V.
출원인 / 주소
Topokine Therapeutics, Inc.
대리인 / 주소
Wolf, Greenfield & Sacks, P.C.
인용정보
피인용 횟수 :
1인용 특허 :
65
초록▼
Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, wh
Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound to subcutaneous fat under the skin, and methods of preparation. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject.
대표청구항▼
1. A method for reducing body fat in a subject, the method comprising administering to the subject a composition comprising latanoprost, isopropyl myristate, and petroleum jelly. 2. The method of claim 1, wherein the method locally reduces body fat in the subject. 3. The method of claim 1, wherein t
1. A method for reducing body fat in a subject, the method comprising administering to the subject a composition comprising latanoprost, isopropyl myristate, and petroleum jelly. 2. The method of claim 1, wherein the method locally reduces body fat in the subject. 3. The method of claim 1, wherein the method reduces subcutaneous fat in the subject. 4. The method of claim 1, wherein the composition consists essentially of latanoprost, isopropyl myristate, and petroleum jelly. 5. The method of claim 1, wherein the latanoprost concentration is between about 0.001% and about 1% w/w, inclusive. 6. The method of claim 5, wherein the latanoprost concentration is between about 0.01% and about 0.5% w/w, inclusive. 7. The method of claim 1, wherein the isopropyl myristate concentration is between about 1% and about 20% w/w, inclusive. 8. The method of claim 7, wherein the isopropyl myristate concentration is between about 1% and about 10% w/w, inclusive. 9. The method of claim 5, wherein the isopropyl myristate concentration is between about 1% and about 20% w/w, inclusive. 10. The method of claim 9, wherein the isopropyl myristate concentration is between about 1% and about 10% w/w, inclusive. 11. The method of claim 1, wherein the petroleum jelly concentration is between about 70% and about 99% w/w, inclusive. 12. The method of claim 5, wherein the petroleum jelly concentration is between about 70% and about 99% w/w, inclusive. 13. The method of claim 1, wherein the composition further comprises a preservative. 14. The method of claim 13, wherein the preservative is chlorobutanol. 15. The method of claim 1, wherein the composition is sterile. 16. The method of claim 1, wherein the latanoprost concentration is between about 0.001% and 1% w/w, inclusive; the isopropyl myristate concentration is between about 1% and about 10% w/w, inclusive; and the petroleum jelly concentration is between about 70% and about 99% w/w, inclusive. 17. The method of claim 1, wherein the step of administering is performed about once a day. 18. The method of claim 1, wherein the step of administering comprises administering the composition to the face, chin, neck, arms, abdomen, chest, breast, buttocks, hips, thighs, legs, and/or knees. 19. The method of claim 1, wherein the step of administering comprises administering the composition to the eyelids. 20. The method of claim 1, wherein the step of administering comprises administering the composition to the submental region. 21. The method of claim 1, wherein the latanoprost concentration is between about 0.03% and about 0.1% w/w, inclusive. 22. The method of claim 21, wherein the composition consists essentially of latanoprost, isopropyl myristate, and petroleum jelly. 23. The method of claim 16, wherein the latanoprost concentration is between about 0.03% and about 0.1% w/w, inclusive. 24. The method of claim 23, wherein the composition consists essentially of latanoprost, isopropyl myristate, and petroleum jelly. 25. The method of claim 1, wherein the latanoprost concentration is about 0.1% w/w. 26. The method of claim 25, wherein the composition consists essentially of latanoprost, isopropyl myristate, and petroleum jelly. 27. The method of claim 16, wherein the latanoprost concentration is about 0.1% w/w. 28. The method of claim 27, wherein the composition consists essentially of latanoprost, isopropyl myristate, and petroleum jelly.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (65)
Feng Zixia ; Hellberg Mark R., 13-Oxa prostaglandins for the treatment of glaucoma and ocular hypertension.
Ling, Kah-Hiing John; Yang, Wu; Ni, Jinsong; Yuan, Haiqing; Tang-Liu, Diane D. S., 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Woodward David F. (El Toro CA) Andrews Steven W. (Rancho Santa Marguerita CA) Burk Robert M. (Irvine CA) Garst Michael E. (Newport Beach CA), Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Tennenbaum, Tamar; Braiman-Wiksman, Liora; Solominik, Inessa; Meir, Michal, Method and compositions for prevention and treatment of diabetic and aged skin.
Pintor, Jesus J.; Peral, Maria A.; Peterson, Ward M.; Plourde, Jr., Robert; Brown, Edward G.; Yerxa, Benjamin R., Method for reducing intraocular pressure using indole derivatives.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
David F. Woodward ; Steven W. Andrews ; Robert M. Burk ; Michael E. Garst, Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents.
Klimko Peter G. ; Bishop John E. ; Sallee Verney L. ; Zinke Paul W., Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension.
Hellberg, Mark R.; Nixon, Jon C., Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.